An experimental drug has shown promising results in extending the lifespan of middle-aged mice by 25%, leading scientists to believe it could have similar effects in humans if further research is conducted. The drug, an antibody called anti-IL-11, was administered to the mice when they were considered ‘middle-aged’ and resulted in a significant reduction in cancer-related deaths as well as a decrease in age-related diseases such as fibrosis, chronic inflammation, and poor metabolism.
Professor Stuart Cook, a senior scientist involved in the study, expressed excitement over the findings, emphasizing that the treated mice displayed signs of improved health, reduced muscle wasting, and increased muscle strength. Videos released by the researchers showcased the stark contrast between untreated mice, which showed signs of aging such as greying fur, hair loss, and weight gain, compared to the mice that received the antibody injection, which had glossy coats and were more active.
The researchers from the Medical Research Council Laboratory of Medical Science, Imperial College London, and Duke-NUS Medical School in Singapore conducted the study by administering the antibody injection to the mice at an equivalent age of 55 years in humans. The results published in the journal Nature revealed that the treated mice lived an average of 35 weeks longer than those not treated, with very few side effects observed.
The drug worked by blocking the action of the IL-11 protein, believed to contribute to the aging process in both mice and humans. Professor Cook highlighted that the gene activity of IL-11 increases with age in all tissues, leading to a range of age-related diseases and loss of bodily functions. Scientists have been exploring ways to slow down the aging process to enhance the overall health and quality of life of individuals, especially as they age.
While other life-extending interventions such as metformin and severe calorie restriction have shown promise in early studies, some experts remain cautious about the potential risks and costs associated with widespread treatment. Professor Ilaria Bellantuono from the University of Sheffield pointed out that more evidence is needed from patient trials to determine the safety and efficacy of these interventions, especially in identifying individuals who are at risk of frailty and would benefit the most.
In conclusion, the groundbreaking results of the experimental drug in extending the lifespan of mice offer a glimpse of hope for similar effects in humans. Further research and clinical trials are essential to validate these findings and explore the potential benefits of anti-IL-11 treatment in aging populations. While challenges remain in translating these interventions to patient care, the quest for enhancing healthy aging and longevity continues to drive scientific advancements in the field.
